Summary
Boston Scientific Corporation (BSX) filed an 8-K on January 31, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The core of this filing is the press release, furnished as Exhibit 99.1, which contains the detailed financial performance. Investors should review this press release for specific revenue figures, profitability metrics, and management's commentary on the company's performance and outlook. While the 8-K itself does not contain the financial details, it officially announces that the information is available. This filing serves as the public notification that BSX has disseminated its latest earnings report. Investors interested in the company's operational and financial standing should refer to the accompanying press release for comprehensive insights into their performance and any forward-looking statements made by the company.
Key Highlights
- 1Boston Scientific announced its Q4 and Full Year 2023 financial results on January 31, 2024, via a press release (Exhibit 99.1).
- 2The 8-K filing serves as notification and filing of the earnings press release.
- 3Investors are directed to Exhibit 99.1 for detailed financial performance, including revenue and earnings.
- 4The filing indicates that the information furnished is not deemed 'filed' for Section 18 purposes, a standard disclaimer for earnings releases.
- 5No other material events or business updates are disclosed in the 8-K filing itself, beyond the earnings announcement.